Should I buy or sell Cullinan Oncology stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks .

What is Cullinan Oncology's stock price target for 2024?

6 equities research analysts have issued 12-month price objectives for Cullinan Oncology's shares. Their CGEM share price targets range from $22.00 to $30.00. On average, they anticipate the company's share price to reach $27.75 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts .

How have CGEM shares performed in 2024?

Cullinan Oncology's stock was trading at $10.19 at the beginning of the year. Since then, CGEM shares have increased by 75.5% and is now trading at $17.88. View the best growth stocks for 2024 here .

Are investors shorting Cullinan Oncology?

Cullinan Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,440,000 shares, an increase of 53.9% from the March 15th total of 935,400 shares. Based on an average trading volume of 423,600 shares, the short-interest ratio is currently 3.4 days. Approximately 5.5% of the company's stock are sold short. View Cullinan Oncology's Short Interest .

When is Cullinan Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CGEM earnings forecast .

How were Cullinan Oncology's earnings last quarter?

Cullinan Oncology, Inc. (NASDAQ:CGEM) issued its earnings results on Thursday, March, 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.96) by $0.42.

What ETF holds Cullinan Oncology's stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 10,181 shares of CGEM stock, representing 1.59% of its portfolio.

When did Cullinan Oncology IPO?

Cullinan Oncology (CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

How do I buy shares of Cullinan Oncology?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CGEM

Cullinan Oncology (CGEM) Stock Price, News & Analysis

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)

Free CGEM Stock Alerts

$17.88

+0.56 (+3.23%)

(As of 04/17/2024 ET)

Compare

Today's Range: $17.61
▼
$19.97
50-Day Range: $15.32
▼
$19.02
52-Week Range: $7.64
▼
$20.62

Volume: 1.26 million shs
Average Volume: 456,405 shs
Market Capitalization: $770.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.75

Get Cullinan Oncology alerts:

Cullinan Oncology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 55.2% Upside
$27.75 Price Target
Short Interest: Bearish
5.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.31
Based on 25 Articles This Week
Insider Trading: Selling Shares
$1.44 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.55) to ($3.37) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

522nd out of 914 stocks

Biological Products, Except Diagnostic Industry

74th out of 138 stocks

3.5

Analyst's Opinion

Consensus Rating
Cullinan Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cullinan Oncology has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.49% of the float of Cullinan Oncology has been sold short.
Short Interest Ratio / Days to Cover
Cullinan Oncology has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cullinan Oncology has recently increased by 53.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cullinan Oncology does not currently pay a dividend.
Dividend Growth
Cullinan Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CGEM.

3.0

News and Social Media Coverage

News Sentiment
Cullinan Oncology has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 25 news articles for Cullinan Oncology this week, compared to 1 article on an average week.
Search Interest
7 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
MarketBeat Follows
4 people have added Cullinan Oncology to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cullinan Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,437,624.00 in company stock.
Percentage Held by Insiders
Only 8.82% of the stock of Cullinan Oncology is held by insiders.
Percentage Held by Institutions
86.31% of the stock of Cullinan Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cullinan Oncology are expected to grow in the coming year, from ($3.55) to ($3.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cullinan Oncology is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cullinan Oncology is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cullinan Oncology has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Cullinan Oncology Stock (NASDAQ:CGEM)

Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CGEM Stock News Headlines

April 17, 2024 | finanznachrichten.de

Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

April 17, 2024 | americanbankingnews.com

Cullinan Oncology (NASDAQ:CGEM) Price Target Cut to $29.00 by Analysts at HC Wainwright

April 17, 2024 | Wall Street Star (Ad)

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

April 16, 2024 | markets.businessinsider.com

Buy Recommendation: Cullinan Management’s Strategic Position in Autoimmune Disease Market with Promising CLN-978 Therapy

April 16, 2024 | bizjournals.com

Cullinan rebrands with $280M private offering, pivot away from cancer

April 16, 2024 | finance.yahoo.com

Cullinan changes name, pivots to autoimmune disease

April 16, 2024 | markets.businessinsider.com

Cullinan To Expand Into Autoimmune Diseases, Privately Places $280 Mln; Stock Up In Pre-Market

April 16, 2024 | markets.businessinsider.com

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

April 17, 2024 | Wall Street Star (Ad)

This Apple-like Innovator is Revolutionizing Healthcare

April 16, 2024 | marketwatch.com

Cullinan Oncology Shares Jump 21% on Planned Autoimmune Diseases Expansion, Private Placement

April 16, 2024 | msn.com

William Blair Initiates Coverage of Cullinan Oncology (CGEM) with Outperform Recommendation

April 16, 2024 | globenewswire.com

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

April 16, 2024 | globenewswire.com

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

April 16, 2024 | americanbankingnews.com

Cullinan Oncology (NASDAQ:CGEM) Receives New Coverage from Analysts at William Blair

April 13, 2024 | americanbankingnews.com

Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $17.06

March 16, 2024 | finance.yahoo.com

Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results

March 15, 2024 | finance.yahoo.com

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

March 14, 2024 | investorplace.com

CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023

March 14, 2024 | finanznachrichten.de

Cullinan Oncology, Inc.: Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 14, 2024 | benzinga.com

Cullinan Oncology: Q4 Earnings Insights

March 14, 2024 | globenewswire.com

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 1, 2024 | markets.businessinsider.com

Cullinan Oncology Announces FDA Clearance Of IND Application For CLN-619

March 1, 2024 | globenewswire.com

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

February 27, 2024 | globenewswire.com

Cullinan Oncology to Participate in Upcoming Investor Conferences

February 12, 2024 | investing.com

Cullinan Oncology LLC (CGEM)

January 31, 2024 | finance.yahoo.com

Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

January 24, 2024 | finance.yahoo.com

Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

See More Headlines

Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CGEM
CUSIP: N/A
CIK: 1789972
Web: www.cullinanoncology.com
Phone: 617-410-4650
Fax: N/A
Employees: 85
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.00
High Stock Price Target: $30.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +39.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-153,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.11%
Return on Assets: -30.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.07
Quick Ratio: 17.07

Sales & Book Value

Annual Sales: $18.94 million
Price / Sales: 44.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.61 per share
Price / Book: 1.83

Miscellaneous

Outstanding Shares: 43,070,000
Free Float: 39,268,000
Market Cap: $835.99 million
Optionable: Optionable
Beta: 0.33

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Nadim Ahmed (Age 56)
President, CEO & Director
Comp: $1.16M
Dr. Jeffrey Jones M.B.A. (Age 53)
M.D., M.P.H., Chief Medical Officer
Comp: $780.32k
Dr. Patrick A. Baeuerle Ph.D. (Age 66)
Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Comp: $763.73k
Dr. Jennifer Michaelson Ph.D. (Age 57)
Chief Scientific Officer
Ms. Jacquelyn L. Sumer J.D. (Age 46)
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Ms. Rose Weldon
Senior Vice President of Communications
Mr. Steve Andre
Chief Human Resources Officer
Dr. Corinne Savill Ph.D. (Age 65)
Chief Business Officer
Mr. Kevin A. Johnston
Chief Technical Operations Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CGEM Stock Analysis - Frequently Asked Questions

Should I buy or sell Cullinan Oncology stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEM shares.
View CGEM analyst ratings or view top-rated stocks.
What is Cullinan Oncology's stock price target for 2024?: 6 equities research analysts have issued 12-month price objectives for Cullinan Oncology's shares. Their CGEM share price targets range from $22.00 to $30.00. On average, they anticipate the company's share price to reach $27.75 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts.
How have CGEM shares performed in 2024?: Cullinan Oncology's stock was trading at $10.19 at the beginning of the year. Since then, CGEM shares have increased by 75.5% and is now trading at $17.88.
View the best growth stocks for 2024 here.
Are investors shorting Cullinan Oncology?: Cullinan Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,440,000 shares, an increase of 53.9% from the March 15th total of 935,400 shares. Based on an average trading volume of 423,600 shares, the short-interest ratio is currently 3.4 days. Approximately 5.5% of the company's stock are sold short.
View Cullinan Oncology's Short Interest.
When is Cullinan Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CGEM earnings forecast.

How were Cullinan Oncology's earnings last quarter?: Cullinan Oncology, Inc. (NASDAQ:CGEM) issued its earnings results on Thursday, March, 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.96) by $0.42.
What ETF holds Cullinan Oncology's stock?: Virtus LifeSci Biotech Clinical Trials ETF holds 10,181 shares of CGEM stock, representing 1.59% of its portfolio.
When did Cullinan Oncology IPO?: Cullinan Oncology (CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.
How do I buy shares of Cullinan Oncology?: Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGEM) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cullinan Oncology (CGEM) Stock Price, News & Analysis

Cullinan Oncology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cullinan Oncology Stock (NASDAQ:CGEM)

CGEM Stock Price History

CGEM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CGEM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™